key: cord-0942558-lnwkvxmx
authors: Migo, William; Boskovic, Marko; Likic, Robert
title: The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response
date: 2021-10-09
journal: Curr Res Pharmacol Drug Discov
DOI: 10.1016/j.crphar.2021.100064
sha: f8ade0c20873eef1ad81aade13ba133062b042dc
doc_id: 942558
cord_uid: lnwkvxmx

Development of novel antibodies to combat the novel SARS-CoV-2 virus is ongoing. Importantly, particular subgroups are more prone to severe disease, namely patients with poor immune responses. This includes cancer patients with solid and haematological disease, solid organ transplant (SOT) patients and those with congenital or acquired immunodeficiency. Outcomes for patients with poor immune responses receiving antibody therapy for underlying disease and SARS-CoV-2 severe infection are undergoing investigation. The objective of this study was to perform a search on patients with poor immune responses with severe SARS-CoV-2 infection, to assess if antibody therapy is beneficial in such populations. We performed searches using PubMED and medrXiv up to May 2021 of patients with solid and hematologic malignancy, SOT patients and acquired or congenital immunodeficiency. The primary outcome was to assess if antibody therapy was included during SARS-CoV-2 infection and the clinical outcomes of such treatment in this population. Here we find that there is a repurposing of monoclonal antibodies to target cytokine release syndrome, along with the use of convalescent plasma (CP). Despite CP demonstrating promising results, we reiterate evidence that CP forces mutational escape and subsequent variant development. Repurposing of antibody therapies (such as Tocilizumab) proved effective, especially in SOT patients. This also potentially opens an avenue for the use of anti-SARS-CoV-2 spike protein neutralizing monoclonal antibodies; however, studies have yet to focus on patients with poor immune responses as a subpopulation.

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was declared a pandemic by the World Health Organisation (WHO) on March 11, 2020 , (WHO, 2020 . Its global spread has challenged the scientific community to repurpose existing monoclonal antibodies (mAb) and develop novel treatments. High risk patients with comorbidities and/or compromised immune systems are at greater risk for severe SARS-CoV-2 infection and represent an important subpopulation in need of appropriate care (Mehta et al., 2020) . Generally, patients older than 60 years, with underlying medical comorbidities (obesity, cardiovascular disease, chronic kidney disease, diabetes, COPD) or immunocompromised states (solid and haematological malignancy, hematopoietic stem cell and solid organ transplant patients) were reported to have hospitalization rates 6 times higher compared to their healthy counterparts (45.4% vs 7.6%) (Stokes, 2020) . In order to prevent higher mortality and address the needs of this at-risk sub-population, treatment regiments should broaden and improve.

Further, those with solid malignancy (especially lung cancer), solid organ transplant (SOT) or on chronic immunosuppressive disease modifying treatment had increased risk of severe outcomes such as secondary bacterial/fungal superinfection, higher ICU admissions, mechanical ventilation with intubation and overall mortality (Waghmare et al., 2016; Fung & Babik, 2021) .

Although this is true for the majority of immunocompromised states, we recognize there is heterogeneity, complexity and exceptions to this. For example, hematopoietic stem cell transplant (HSCT) patients demonstrate a similar severity score compared to their healthy counterparts (Albiges et al., 2020; Belsky et al., 2021) . Whether this is due to their current J o u r n a l P r e -p r o o f Page 4 of 30 immunosuppressive regimen has still yet to be fully elucidated and paints a more complex picture.

Patients with poor immune responses owing to underlying disease and/or immunosuppressive therapy are at increased risk for severe infection, often coupled with Cytokine Release Syndrome (CRS). CRS is characterised by fever, hyperferritinemia and a cytokine storm (namely, increased production of IL-6, TNF-a and monocyte chemoattractant molecules).

Importantly, Huang et al concluded that disease severity is correlated with hypercytokinaemia with characteristic increases in specific serum interleukin profiles in ICU patients (IL-2, IL-7, IL-10, G-CSF, MCP-1, IFN-y, TNF-a, ferritin and IL-6) compared to non-ICU patients (Wan et al., 2020; Huang et al., 2020; Coperchini et al., 2020) . During these hyper-inflammatory states, SARS-CoV-2 patients were found to have an exhausted immune system with decreased monocyte and CD4+/ CD8+ T cell count (lymphopenia) and pathogenic TH1 cells resulting in increased cytokine parameters. Overall, a lymphopenic and hypercytokinaemia profile definitively suggests a severe SARS-CoV-2 infection with poor prognosis and these inflammatory parameters are now used to guide treatment (Coperchini et al., 2020) .

Interestingly, this association between SARS-CoV-2 infection and CRS has steered treatment towards immunosuppression via CRS specific mAbs benefiting patients by reducing proinflammatory reactivity and subsequently abating the storm. Additionally, a more preventative approach, especially significant in immunocompromised patients, might include Neutralizing mAbs (NMAbs) that target the SARS-CoV-2 receptor binding domain (RBD) and prevent severe disease developing. Currently, several pharmaceutical companies are trialing repurposed mAbs that target the CRS and are under investigation in patients with poor immune responses (table 1.1). There is also research demonstrating clinical efficacy with convalescent plasma (CP) administration in these patients. However, we must acknowledge the potential for mutational escape, especially recent data observing the emergence of multiple SARS-CoV-2 antibody escape variants in immunocompromised hosts undergoing CP treatment (Baum et al., 2020; Chen et al., 2021; Khatamzas et al., 2021) . Targeting both SARS-CoV-2 RBD with NMAb's/ CP, while suppressing the CRS with repurposed mAbs, provides a robust multi-hit mechanism in preventing severe disease. Although the FDA recently granted emergency use authorisation for CP in nonhospitalized patients with mild-to-moderate SARS-CoV-2 infection, it is still not known the extent to which mAb therapies will improve outcomes in at-risk patients. It is also recognized that the type of immunosuppressant therapy in these patients does not always correspond to severe disease and is increasingly complex. More research is needed in order to explore these intricacies and guide treatment plans in immunocompromised patients with SARS-CoV-2 infection.

The expansion of prophylactic therapy for SARS-CoV-2 in patients with poor immune responses is increasingly prudent. Poor vaccine immunogenicity and the growing threat of mutational escape globally is forcing the development of alternative targets in the form of immunotherapy as previously described. According to a recent review patients with hematological and solid cancers demonstrate reduced immunogenicity to SARS-CoV-2 vaccinations. This is a constant trend echoed amongst other vaccines, for example, acute J o u r n a l P r e -p r o o f Page 6 of 30 lymphoblastic leukemia (ALL) patients had 10-27% immunogenicity after hepatitis B and meningococcal subunit vaccines (Yu et al., 2007) . Further, annual influenza vaccinations for haematological cancer patients demonstrated 10-42% response (Goyal et al., 1998) . Boyarsky et al (2021) report 17% of patients developing anti-SARS-CoV-2 antibodies in response to an initial dose of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna). We acknowledge the limited data on this topic but clinical trials are underway, observing immunological response in immunocompromised patients (table 1.2). Table 1 .1 and figure 1.1 show potential targets of the CRS. Finally, it is agreeable that urgent discussion is required about the growing potential of novel mAb therapies, in order to develop strategies on how to use them effectively during clinical practice. Specifically, this relates to safety and production, availability and eventual distribution of mAbs. There is also a need to dissect the complex interactions of immunosuppressive drugs in simultaneously controlling underlying disease (for example chemotherapy for long-term rheumatic patients) and the SARS-CoV-2 CRS in an effort to improve understanding and clinical outcome in these patients. Clinicians are altering immunosuppressive drug regimens to understand this and find ways that do not compromise treatment of underlying conditions in these patients. Here we discuss the data and results surrounding targeted mAb treatment for severe SARS-CoV-2 patients with poor immune responses. conditions. Key words used in each search were: "COVID-19", "SARS-CoV-2", "convalescent plasma", "neutralising antibodies", "antibodies", "immune deficiency", "monoclonal antibodies", "cancer", "hypogammaglobulinaemia", "immunocompromised", "transplant", "kidney transplant", "heart transplant". Importantly, we also utilised reference lists from other review/primary research articles in order to attain additional relevant information previously not captured from our initial search. We primarily focus on clinical outcome, side effect profile and the efficacy of drug administration. 

The process of creating a novel mAb is complex, composing of animal and human testing.

Firstly the target is identified for the antibody. NMAbs inhibit SARS-CoV-2 through inhibiting the viral spike protein (S-protein, specifically S1 subunit, fig 1. 3) and subsequent viral entry (Baum et al., 2020; Hansen et al., 2020; Lan et al., 2020; Huang et al., 2020) .

After identifying a target, validation is confirmed through animal models using Bacterial Artificial Chromosomes (Bac) (Shizuya & Kouros-Mehr, 2001) . This is where Bac is inserted into the genome in order to encode and produce humanized variable regions responsible for antibody production. The newly altered genome, or BacVec is then delivered into mice embryonic stem cells (ESCs), which replaces a portion of the mouse's original genome (capecchi, 1989) .

ESCs are filtered and selected for desired genetic modifications. These are inserted into murine embryos at an early stage of development. This results in subsequent murine progeny having the ability to create novel antibodies. Next, the target protein can be introduced.

One introduced, the target protein is identified and the new genome codes for the production of new antibodies. These are harvested and filtered via flow cytometry. Once viable antibodies are discovered, they are tested firstly in preclinical trials (safety and efficiency) and finally onto human trials.

Antibody therapy in patients with poor immune responses Importantly, we recognize that immunosuppressive therapies have differing mechanisms of action on the immune system. A recent meta-analysis found no evidence of improvement of severe SARS-CoV-2 disease under treatment with TNF-blockers, IL-1 blockers or IL-6 blockers (Haberman et al., 2020; Russel et al., 2020) . This perhaps suggests the requirement for a specific deficiency or abnormality in humoral immunity that then predisposes to severe disease as opposed to complete immunosuppression. This creates a more intricate roadmap and should be interrogated further. From our review of existing literature and ongoing clinical trials to date, we can see that there may be some benefit in modifying immunosuppressive regimens in order to control SARS-CoV-2 severe disease.

As previously mentioned, data demonstrates patients with solid and haematological cancers are more prone to severe presentations, outcomes and higher mortality rates in comparison to general population (Kuderer et al., 2020; Lee et al, 2020; Tian et al., 2020 , Mehta et al., 2020 .

Further, recent cancer treatment did not seem to significantly increase the risk of death (Vijenthira et al., 2020) . One important clinical question is how to manage patients who need anticancer therapy during SARS-CoV-2 infection. Selinexor inhibits nuclear export while Lenzilumab is a mAb that targets CSF2/GM-CSF. This is a multi-centre trial with four main arms, expecting to provide insight into the best practice for prevention and treatment of SARS-CoV-2 in cancer patients as emerging standard of care measures are not always suitable to this especially vulnerable population. Finally, a recent phase two trial (NCT04370834) assessed the effect of Tocilizumab in reducing inflammation associated with CRS seen in severe SARS-COV-2 infection in cancer patients.

However, recent r11andomized data no longer supported its continuation.

Overall, despite the positive results in many case studies/ case-reports, there is still a lack of data surrounding cancer patient use of monoclonal antibodies to treat SARS-CoV-2 proinflammatory CRS. Specifically, large 11randomized control trials are needed in order to draw more robust and reliable conclusions.

We have established patients lacking humoral response develop prolonged and a more severe course of infection. Since the onset of the pandemic, there is some evidence of the beneficial effects of mAbs and CP for patients with poor immune responses. Delgado-Fernandez et al (2021) report highly effective response rate from CP administration, demonstrating reduced relapse rates and chronicity (Kemp et al., 2021) . Further studies indicate that clinical outcome in three SOT patients following CP administration [43] . Before receiving CP, patients developed severe SARS-CoV-2 infection (some requiring intubation). However, upon administration of CP all patients recovered without significant sequelae/side effects relating to CP. Prednisone was maintained while other immunosuppressive drugs were discontinued on admission as prednisone's anti-inflammatory effects act to minimise the alveoli infiltration, reducing the risk of acute respiratory distress syndrome (ARDS) and subsequent potential CRS (Naeem et al., 2021) .

MAbs have also demonstrated improved clinical outcome in SOT patients. A recent case study observed effect of tocilizumab in a series of kidney transplant patients with severe respiratory SARS-CoV-2 infection. Despite 4 of 6 patients eventually succumbing to their underlying condition, C-reactive protein was reduced in all patients without significant modification in LDH or D-Dimer. IL-6 was reduced in 4/6 patients. Furthermore, in the 2 surviving patients, a significant increase in lymphocyte count was observed, supporting the notion that restoring lymphocyte activity is critical for obtaining a favourable outcome (Mella et al., 2020) . Another case study conducted by Faguer et al (2020) observed the effect of tocilizumab in a kidney transplant patient who developed haemophagocytic syndrome following SARS-CoV-2 infection. Upon multi-organ failure, administration of tocilizumab resulted in dramatic improvement and rapid reversal of respiratory, haemodynamic and liver conditions and correction of ferritin levels (Faguer et al., 2020) . Another recent case study showed complete recovery from SARS-CoV-2 illness in a heart transplant patient following mAb administration.

After rapid respiratory deterioration with increased inflammatory markers (CRP/ IL-6), the patient received 25mg IV clazakizumab, an IL-6 inhibitor now in phase 2/3 clinical trials J o u r n a l P r e -p r o o f Page 14 of 30 (NTC04348500 and NTC04343989). The patient subsequently improved and was later discharged (Vaidya et al., 2020) . This was echoed in another case report describing recovery of a heart transplant patient receiving tocilizumab (Mattioli et al., 2020) . Belsky et al. (2021) conducted a recent meta-analysis of patients with poor immune responses exploring current therapeutic management. Accordingly, IL-6 blockage was reported the most amongst subpopulations and especially in SOT populations (n=120). They also noted a common therapeutic intervention whereby baseline immunosuppression was either modified or delayed.

Currently, a multicentric clinical trial is aiming to better understand the incidence, risk factors, A safety concern related to the preventing the spread of SARS-CoV-2 is the emergence of viral escape mutations. Viral escape is when under the pressure of medication, the virus mutates in order to evade neutralization. As S-protein variants that resist neutralization are now present at low frequencies in circulating SARS-CoV-2 populations, monoclonal antibody combinations as opposed to polyclonal CP are favored to mitigate viral escape (Weisblum et al., 2020) . The combination NMAbs such as BRII-196/BRII-198 and REGN-COV2 are stated to prevent viral escape by binding to two distinct neutralizing epitopes (Baum et al., 2020 , Hansen et al., 2020 .

In this instance, in order for viral escape to take place, two simultaneous viral mutations at two separate distinct genetic sites would need to take place.

Page 17 of 30

Here we review the latest data on monoclonal antibody therapy in patients with poor immune responses following severe SARS-CoV-2 infection. It is evident that the number of studies conducted is limited. Results from case reports and cohort studies in this review tell us how treatment regimens of underlying conditions are being altered on an individual basis in order to prevent the otherwise deleterious effects of complete treatment cessation.

Tocilizumab appears to be leading SARS-CoV-2 mAb therapy, with ability to control CRS and reduce proinflammatory markers with subsequent resolution of severe disease. Despite inadequate data, CP also appears to prevent SARS-CoV-2 CRS. However, it is important to remain cautious due to increased mutational escape rates resulting from increased selective pressures (Weisblum et al., 2020; Rnjak et al., 2021) .

Currently, it seems that clinical trials are focused on the effect of SARS-CoV-2 infection in immunocompromised patients clinically (i.e severity, response to current therapies and clinical outcome) and their ability to mount an immune response to current vaccinations. Outcomes of such patients are improving owing to biological therapies that target immune response against malignant disease, as well as supportive care and cellular therapies seen in SOT patients. These same treatments are being used in patients with severe SARS-CoV-2 infection in order to control the CRS clinical picture. Importantly, alterations in immunosuppressive therapies could negatively impact primary disease outcomes in these patients.

Overall, we recognise that the field surrounding this topic is rapidly evolving. With our discussion and conclusions based on case reports and cohort studies, we acknowledge the J o u r n a l P r e -p r o o f

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☐ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients

Immunogenicity of a Single Dose of SARS-CoV-2 mRNA Vaccine in Solid Organ Transplant Recipients

Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls

Emergence of multiple SARS-CoV-2 antibody escape variants in an immunocompromised host undergoing convalescent plasma treatment

Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients -Full Text View -ClinicalTrials.gov

Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab

The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system

Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells

Perfil de seguridad y aspectos prácticos a tener en cuenta en la administración de anticuerpos monoclonales

Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19. Annals of internal medicine

Emergency Use Authorization (EUA) of casirivimab and imdevimab

COVID-19 in Immunocompromised Hosts: What We Know So Far

Hepatitis B vaccination in acute lymphoblastic leukemia

Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation? American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Covid-19 in Immune-Mediated Inflammatory Diseases -Case Series from New York. The New England journal of medicine

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19'

SARS-CoV-2 evolution during treatment of chronic infection

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

Multimodality treatment in immunocompromised patients with severe COVID-19: the role of IL-6 inhibitor, intravenous immunoglobulin, and haemoperfusion

Heart transplant recipient patient with COVID-19 treated with tocilizumab. Transplant infectious disease : an official journal of the Transplantation Society

Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer discovery

Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer discovery

Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab

Altering the genome by homologous recombination

Emergence of multiple SARS-CoV-2 mutations in an immunocompromised host

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy

COVID-19 convalescent plasma as long-term therapy in immunodeficient patients? Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine

Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19. The Lancet

Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence

The development and applications of the bacterial artificial chromosome cloning system. The Keio journal of medicine

Coronavirus Disease 2019 Case Surveillance -United States

PRIME PubMed: Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. PRIME PubMed | Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan

Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

d.). How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation

Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)

Outpatients with Covid-19. The New England journal of medicine

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

WHO Director-General's opening remarks at the media briefing on COVID-19 -11

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Immune response to conjugated meningococcal C vaccine in pediatric oncology patients